A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer

Alessandra Tognoni, L. Cadenotti, F. Pensa, F. Vaira, A. Vigani, L. Bancalari, S. Cordani, R. Maggiani, P. A. Canessa, P. Pronzato

Research output: Contribution to journalArticle

Abstract

Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m 2 days 1-3, ifosfamide 1500 mg/m 2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m 2 days 1 and 5; filgrastim was given at the dose of 300 μg subcutaneously from day 8 to day 15. A response rate of 28% was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.

Original languageEnglish
Pages (from-to)306-309
Number of pages4
JournalJournal of Chemotherapy
Volume11
Issue number4
Publication statusPublished - 1999

Keywords

  • Cisplatin
  • Dose intensity
  • Filgrastim
  • Ifosfamide
  • Lung cancer
  • Mesna
  • Non-small-cell lung cancer (NSCLC)
  • Vinorelbine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer'. Together they form a unique fingerprint.

Cite this